Inclusion criteria for larotrectinib

Larotrectinib (Larotrectinib) is a targeted therapy drug used to treat TRK (neuronal growth factor receptor) gene fusion-positive tumors. Enrollment refers to a set of criteria that patients must meet to determine whether they are suitable for this treatment. The following are general highlights of enrollment criteria that generally apply to larotrectinib treatment:

1.TRKgene fusion test positive: The first requirement for enrollment is that patients must undergo genetic testing, and the results show that there is TRKgene fusion in their tumors. This usually involves collecting a sample of the tumor and performing molecular biology or genetic testing to confirm the presence of the TRK gene fusion.

2.Unresectable or metastatic: Larotrectinib is typically used in patients whose tumors cannot be removed by surgery due to their location or progression, and in patients whose tumors have spread to other sites (metastasis).

3.Appropriate age range: Larotrectinib was clinically tested and approved for both pediatric and adult patients.

4.Basic physical condition: Patients must have sufficient basic physical health to be able to tolerate larotrectinib treatment. This may include normal liver function, kidney function, and bone marrow function.

5.Not allergic to drug ingredients: Patients must not be allergic to any ingredient of larotrectinib or have had a severe allergic reaction.

6.No serious cardiovascular problems: Patients must not have serious heart problems as larotrectinib may have an impact on heart function.

7.No other serious complications or diseases: Patients should not suffer from other serious diseases or complications at the same time, which may affect the safety and efficacy of larotrectinib.

8.Not During Pregnancy or Breastfeeding: Larotrectinib may have adverse effects on the fetus, so use of this medication is generally not recommended in pregnant or breastfeeding women.

It should be emphasized that enrollment conditions may vary depending on different clinical trials or specific medical settings. The purpose of the enrollment criteria is to ensure that patients can benefit from treatment with larotrectinib while minimizing potential risks. Patients and physicians should discuss eligibility and suitability for treatment with larotrectinib. Treatment decisions should be individualized and based on the patient's specific circumstances.

Larotrectinib has been launched in China, but it has not been included in medical insurance. Since it has not been launched in China for a long time, it may be difficult to purchase it in China. Please consult the local hospital pharmacy for details. There are original drugs and generic drugs of larotrectinib abroad. The original drugs include German version, American version, European version and Hong Kong version. The price is basically around 20,000 yuan. Generic drugs include Lao and Bangladeshi versions, with prices ranging from two to three thousand. The ingredients of original drugs and generic drugs are basically the same.